By Emma Murray and Tim Heverin

Last week, the Federal Circuit denied a motion to vacate and remand an IPR decision under Arthrex, Inc. v. Smith & Nephew, Inc.   

Issued on October 31, Arthrex held that the method for appointing PTAB Administrative Patent Judges violated the Appointments Clause.  Arthrex purported to fix the Appointments Clause issue by removing certain employee protections from APJs, making APJs terminable at will by the USPTO Director and therefore not subject to the Appointments Clause.  Following the decision, certain Federal Circuit appellants have moved that the Court vacate and remand Board decisions under Arthrex, to be reheard by a different PTAB panel.

In denying the motion, the Federal Circuit relied on Customedia Technologies, LLC v. Dish Network Corporation, 941 F.3d 1174 (Fed. Cir. 2019), which held that a party failing to raise the Arthrex Appointments Clause issue in its opening brief forfeits the challenge.  As was the case in Customedia, the opening brief was filed before the Arthrex opinion and did not raise the Appointments Clause issue.

Dissenting from the majority opinion, Judge Newman explained the timing problem:  “[A]t the time these appeals were filed, there was no holding of illegality of appointments of the PTAB’s Administrative Patent Judges.”  Order at 12.  Judge Newman further quoted that “when the law changes when a case is on appeal, the changed law applies.”  Id.  Accordingly, Judge Newman opined that the requester should be entitled to the same benefit of the Arthrex decision as are the Arthrex parties.  Id.  “The foundation of a nation ruled by law,” Judge Newman wrote, “is that the same rules, as well as the same law, will be applied in the same way to parties in pending litigation.”  Id.

The following two tabs change content below.
For 20 years, Tim Heverin has represented clients in high-value patent and trade secret disputes, often involving international actors, activity, and witnesses. Tim has extensive experience litigating life science patent disputes. He has represented clients in matters concerning pharmaceutical and biologic products such as Prezista®, Hytrin®, Tricor®, Istodax®, and Kuvan®. He recently was part of the team that successfully defeated an institution of four IPRs and defended a separate interference action related to formulation patents for top-selling drug, Humira®.